Results from the VERTIS SITA2 combination study for Merck & Co. Inc./Pfizer Inc.'s SGLT-2 inhibitor ertugliflozin will add to the range of trials that will support regulatory filings – a range the companies have kept broad with the aim of covering the broad spectrum of type 2 diabetes with the initial submission.
The partners aim to file the drug as a monotherapy as well as part of two fixed-dose combinations – with...